PREVALENCE AND ANTIPSYCHOTIC DRUG PRESCRIPTION FOR TREATMENT RESISTANT SCHIZOPHRENIA
Keywords:
prevalence, treatment resistant schizophrenia, antipsychotic drug prescriptionAbstract
Objective: Study performed to assess prevalence and antipsychotic drug prescription for treatment resistant schizophrenia inpatient at Somdet Chaopraya Institute of Psychiatry.
Material and method: The descriptive cross-sectional study obtained data from medical records and interview of patient that admission at Somdet Chaopraya Institute of Psychiatry between 15 November 2015 and 15 May 2016. Patients must have the diagnosis of schizophrenia (ICD-10 coding of F20.0 – F20.9) and evaluate for criteria of treatment resistant schizophrenia. Drug prescription were collected and severity of illness using BPRS and CGI-S, personal function using Personal and social performance scale, Thai Version (Thai-PSP). Percentage, prevalence, mean, standard deviations were used as statistical analysis.
Results: From all of the 524 patients, the 51 patients (9.7%) meet for criteria of treatment resistant schizophrenia. Of these, the 23 patients (45.1%) were male and 28 patients (54.9%) were female. The mean of BPRS was 53.57 ± 8.06. Most results of CGI-S were marked ill (88.2%). The mean of age onset 26.69 ± 6.60 year. Of all antipsychotics prescribed, 35 patients (68.7%) were in group that used 1 antipsychotic. Of these group, clozapine was the most antipsychotic prescribed (47.1%). The mean dose of clozapine in these group was 322.92 ± 119.54 mg/day. Another group were prescribed >1 antipsychotics (16 patients, 31.3%). The 25 patients (49.1%) were treated with long acting antipsychotic. The 19 patients (37.2%) were treated with electroconvulsive therapy (acute-ECT 17 patients, maintenance-ECT 2 patients).
Conclusion: About data of prevalence and antipsychotic drug prescription for treatment resistant schizophrenia, these are basic information for planning of management in treatment resistant schizophrenia.
References
Lindenmayer JP, Khan A. Psychopathology. Lieberrman JA ST, Perkins DO, eds, editor. Washington DC American Psychiatric Publishing; 2006.
Itil TM, Keskiner A, Fink M. Therapeutic studies in “therapy resistant” schizophrenic patients. Compr Psychiatry 1966; 7(6): 488-93.
Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16(4): 551-61.
Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50(11): 898-911.
Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161(2 Suppl): 1-56.
Barnes TR, McEvedy CJ. Pharmacological treatment strategies in the non-responsive schizophrenic patient. Int Clin Psychopharmacol 1996; 2: 67-71.
Conley RR, Kelly DL. Treatment of the special patient with schizophrenia. Dialogues Clin Neurosci 2001; 3(2): 123-35.
Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993; 29(2): 309-14.
Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167(6): 686-93.
Sadock BJ, Sadock VA, Ruiz P. Comprehensive textbook of psychiatry. 9th ed. 2009; 1042-6.
Busner J, Targum S. The clinical global impressions scale: Applying a research tool in clinical practice: psychiatry; 2007.
Srisurapanont M, Arunpongpaisal S, Chuntaruchikapong S, Silpakit C, Khuangsirikul V, Karnjanathanalers N, et al. Cross-cultural validation and inter-rater reliability of the personal and social performance scale, Thai version. J Med Assoc Thai 2008; 91(10): 1603-8.
Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50(11): 898-911.
Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry 1997; 154: 475-82.
Henna NJ, Elkis H. Clinical aspects of super-refractory schizophrenia: a 6-month cohort observational study. Rev Bras Psiquiatr 2007; 29: 228-32.
De Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Res 2005; 76: 135-57.
Salokangas RKR, Honkonen T, Stengard E, Koivisto AM, Hietala J. Cigarette smoking in long-term schizophrenia. Eur Psychiatry 2006; 21: 219-23.
Green AI, Brown ES. Comorbid schizophrenia and substance abuse. J Clin Psychiatry 2006; 67(9): e08.
Castro AP,Elkis H. Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. Rev Bras Psiquiatr 2007; 29: 207-12.
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45(9): 789-96.
Breier A, Buchanan RW, Irish D, Carpenter WT. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44(12): 1145-9.
Zheng W, Cao XL, Ungvari GS, Xiang Y, Guo T, Liu Z, et al. Electroconvulsive therapy added to non-clozapine antipsychotic medication for treatment resistant schizophrenia: meta-analysis of randomized controlled trials. Plos One 2016: 10.
Downloads
Published
How to Cite
Issue
Section
License
The articles published are copyright of Journal of Somdet Chaopraya Institute of Psychiatry.
